VILLA GUARDIA, Italy, Dec. 29, 2011 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the “Company”) today provided an update on the European Marketing Authorization Application for Defibrotide (the “MAA”) to treat and prevent hepatic veno-occlusive disease (VOD) in adults and children undergoing haematopoietic stem-cell transplantation therapy.